HPM Partners LLC acquired a new stake in Fresenius Medical Care Corporation (NYSE:FMS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,568 shares of the company’s stock, valued at approximately $221,000.

A number of other large investors have also recently made changes to their positions in the stock. Fragasso Group Inc. lifted its position in Fresenius Medical Care Corporation by 7.4% in the second quarter. Fragasso Group Inc. now owns 20,764 shares of the company’s stock valued at $1,003,000 after purchasing an additional 1,422 shares during the period. Kayne Anderson Rudnick Investment Management LLC purchased a new position in Fresenius Medical Care Corporation in the second quarter valued at about $1,855,000. Sawtooth Solutions LLC increased its holdings in Fresenius Medical Care Corporation by 2.9% in the second quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock valued at $236,000 after buying an additional 137 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Fresenius Medical Care Corporation by 3.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 78,910 shares of the company’s stock valued at $3,814,000 after buying an additional 2,491 shares in the last quarter. Finally, FFT Wealth Management LLC purchased a new position in Fresenius Medical Care Corporation in the second quarter valued at about $201,000. Hedge funds and other institutional investors own 2.61% of the company’s stock.

Fresenius Medical Care Corporation (FMS) opened at 48.31 on Tuesday. The stock has a market capitalization of $29.65 billion, a PE ratio of 21.27 and a beta of 0.48. The firm has a 50-day moving average of $46.77 and a 200-day moving average of $45.68. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by $0.05. The company had revenue of $4.47 billion during the quarter, compared to analyst estimates of $5.20 billion. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.96 earnings per share. On average, equities research analysts forecast that Fresenius Medical Care Corporation will post $2.35 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/12/hpm-partners-llc-acquires-shares-of-4568-fresenius-medical-care-corporation-fms.html.

A number of research analysts have issued reports on the stock. Zacks Investment Research cut shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 16th. Royal Bank Of Canada reaffirmed a “neutral” rating and issued a target price on shares of Fresenius Medical Care Corporation in a report on Tuesday, August 8th. DZ Bank AG reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. BidaskClub cut shares of Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, UBS AG reaffirmed a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $48.67.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care Corporation (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.